Tag:
Entereg
Latest Headlines
Latest Headlines
Adolor cuts 30 jobs as Entereg sales falter
Exton, PA-based Adolor is cutting 30 jobs, or about a third of its workforce, as it attempts to reduce cash burn levels. The developer had 114 employees at the end of 2009. In May 2008, the FDA
FDA finally gives thumbs-up to Entereg
GlaxoSmithKline and Adolor reached the Entereg summit. After a four-year climb, the two companies finally got FDA approval to sell the anti-constipation drug Entereg. It's OK'd for use after
FDA OKs Adolor's Entereg in first approval
Exton, PA-based Adolor hit a major milestone with the FDA's approval of Entereg for postoperative ileus, a common condition following surgery that can extend a patient's hospital stay. This is the
FDA delays Entereg decision
GlaxoSmithKline and Adolor's seemingly never-ending effort to win approval for Entereg has hit yet another delay. The FDA informed the companies that it would not make a decision by Saturday, the
GSK, Adolor face another Entereg delay
The FDA has told Adolor and GSK that it will take three more months to review Entereg, a anti-constipation drug candidate. The agency is now expected to announce its decision on May 10. Recently, an
ALSO NOTED: Adolor shares rise on NDA news; Indevus plans Phase III; Exelixis earns milestone; and much more...
> Shares of Adolor surged on the news that the FDA's Gastrointestinal Drugs Advisory Committee will review the new drug application for the pain drug
ALSO NOTED: Vernalis reports "striking" weight loss in trial; Genmab shares surge on Phase III; FDA wants more time on Entereg;
>Â Vernalis is reporting "striking" weight loss results in its Phase I trial of the obesity drug V24343.
Investors cheer FDA's acceptance of Entereg response
Shares of Adolor took off this morning, climbing 18 percent after the company issued a joint release with GlaxoSmithKline that the FDA had accepted their response to the agency's
